followed by ATAC-seq assay in SSc ECs identified key HDAC5-regulated genes involved in angiogenesis and fibrosis, such as CYR61, PVRL2, and FSTL1. Simultaneous knockdown of HDAC5 in conjunction with either CYR61, PVRL2, or FSTL1 inhibited angiogenesis in SSc ECs. Conversely, overexpression of these genes individually led to an increase in tube formation as assessed by Matrigel assay, suggesting that these genes play functional roles in the impairment of angiogenesis in SSc.
Conclusion. Several novel HDAC5-regulated target genes associated with impaired angiogenesis were identified in SSc ECs by ATAC-seq. The results of this study provide a potential link between epigenetic regulation and impaired angiogenesis in SSc, and identify a novel mechanism for the dysregulated angiogenesis that characterizes this disease.
Systemic sclerosis (SSc; scleroderma) is a poorly understood autoimmune disease that is characterized by vascular injury and debilitating tissue fibrosis. Activation of endothelial cells (ECs) and inflammatory cells, as well as fibroblasts, leads to excessive production of extracellular matrices, which accumulate in various organs. Widespread vascular damage appears to be an early disease event, as morphologic changes in the vasculature occur before the onset of tissue fibrosis. This is supported by the early presentation of Raynaud's phenomenon, a condition that occurs as the first symptom in almost all patients with SSc, prior to the occurrence of fibrosis. Other vascular complications include pulmonary arterial hypertension and scleroderma renal crisis, both of which contribute significantly to mortality in SSc (1) .
In the skin, SSc vasculopathy leads to loss of dermal capillaries, resulting in tissue hypoxia and ischemia, which, under normal circumstances, prompts angiogenesis.
However, in SSc, this compensatory process is impaired and the ECs are incapable of building new blood vessels (2) . The mechanism of dysregulated angiogenesis in SSc ECs appears to be multifactorial. These mechanistic factors include altered expression of angiogenic-related proteins and transcription factors (2) (3) (4) , impairment of the urokinase-type plasminogen activator receptor pathway (2) , defects in the basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) pathways (2, (5) (6) (7) , and changes in chemokine and chemokine receptor expression and signaling (2, 4, 8) . In addition, SSc ECs can promote fibroblast activation via the CCN2/transforming growth factor b (TGFb) pathway (9) . Epigenetic mechanisms of SSc EC dysfunction have also been noted, as evidenced by the fact that the lower expression of bone morphogenetic protein receptor type II in these cells can be modified by inhibitors of DNA methyltransferase and histone deacetylase (HDAC) (10) .
Emerging data on the role of epigenetics in angiogenesis are beginning to shed light on the effects of abnormal angiogenesis in different diseases. Specifically, HDACs, which enzymatically remove acetyl groups from histones, appear to play significant roles in blood vessel formation. It was reported that nonselective inhibitors of HDACs reduce tube formation of ECs in vitro, inhibit postnatal neovascularization in response to hypoxia, and block tumor angiogenesis (11) . Moreover, the enzymatic activity of class I and class II HDACs is essential for endothelial commitment of progenitor cells (11) . Studies in which individual HDACs were examined in ECs revealed that class IIa HDACs (HDAC-5, HDAC-7, and HDAC-9), class IIb HDACs (HDAC-6), and class III HDACs (SIRT-1) are involved in angiogenesis (11) . They have been shown to affect endothelial functions, including EC proliferation, migration, and apoptosis. Among them, HDAC-5 is antiangiogenic, since knockdown of HDAC5 messenger RNA (mRNA) resulted in EC migration and sprouting (12) . It appears that HDAC5 represses a number of angiogenic genes, such as SLIT2 (gene for Slit homolog 2 protein) and FGF2 (gene encoding fibroblast growth factor 2; also known as bFGF), by binding to their promoter region (12) .
In this study, we examined the role of HDAC-5 in impaired angiogenesis in SSc ECs. We first examined the expression of HDAC5 in ECs isolated from healthy volunteers or patients with diffuse cutaneous SSc, and assessed whether knockdown of HDAC5 mRNA in SSc ECs would alter their angiogenic ability. We then utilized an unbiased approach to assess chromatin accessibility and identify target genes repressed by HDAC5 in ECs, followed by bioinformatics analyses and experimental validation of the identified targets. Several HDAC5-regulated genes that play a critical role in dysregulated angiogenesis in SSc were identified.
PATIENTS AND METHODS
Patients. All patients met the American College of Rheumatology/European League Against Rheumatism criteria for the classification of SSc (13) . The demographics and clinical characteristics of the enrolled patients are summarized in Table 1 . Two 4-mm punch biopsy specimens from the distal forearm of healthy volunteers and patients with diffuse cutaneous SSc were obtained for EC isolation. All subjects included in this study signed a written informed consent. All procedures in this study were reviewed and approved by the Institutional Review Board of the University of Michigan.
Cell culture. Dermal ECs were isolated and characterized in our laboratory in a manner as previously described (4, 6) . After digestion, ECs were purified using a CD31 MicroBead kit and a MiniMACS Separator with an MS Column (Miltenyi Biotech), and grown in EBM-2 medium with growth factors (Lonza). Cells between passages 3 and 6 were used in the experiments.
Extraction of mRNA and quantitative polymerase chain reaction (qPCR). Total RNA from cells was isolated using a Direct-zol RNA MiniPrep kit (Zymo Research) or RNeasy Mini kit (Qiagen). A Verso complementary DNA (cDNA) synthesis kit was used to prepare cDNA (Thermo Scientific). Primers for human HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10, VEGF, and b-actin, along with Power SYBR Green PCR Master Mix (Applied Biosystems), were applied for qPCR, which was run using either a ViiA 7 Real-Time PCR system or an Applied Biosystems Real-Time PCR system. Primer sequences are as follows: for HDAC4, forward TGTACGACGCCAAAGATGAC and reverse CGGT-TCAGAAGCTGTTTTCC; for HDAC5, forward CAGCAG-GCGTTCTACAATGA and reverse CGATGCAGAGAGA-TGTAGAGCA; for HDAC6, forward GAAAGTCACCTCGG-CATCAT and reverse TAGTCTGGCCTGGAGTGGAC; for HDAC7, forward ATGGGGGATCCTGAGTACCT and reverse GATGGGCATCACGACTATCC; for HDAC9, forward CTGG-AGCCCATCTCACCTT and reverse TCATCATCCTGAGGTC- Western blots. Cell lysates were obtained both from healthy subjects and from patients with SSc. Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membranes. HDAC-5 proteins were detected using antihuman HDAC-5 antibodies (Cell Signaling Technology), while b-actin was used as a loading control (anti-b-actin antibodies were from Sigma-Aldrich). Band quantification was performed using GelQuant.NET (BiochemLab Solutions).
Gene knockdown experiments. To evaluate the effect of HDAC-5 on angiogenesis in SSc ECs, its expression was knocked down using HDAC5 small interfering RNA (siRNA) (Santa Cruz Biotechnology), while a nontargeted siRNA (Life Technologies) was used as a control. We first utilized ECs from healthy subjects to establish the transfection condition. ECs were transfected with 25-75 nM of siRNA using TransIT-TKO transfection reagent (Mirus Bio) for 48 hours, and mRNA/protein lysates were collected. We then confirmed the knockdown of HDAC5 using SSc ECs. The knockdown condition was also optimized for experiments using PVRL2 siRNA (50 nM), CTNNAL1 siRNA (50 nM), FSTL1 siRNA (25 nM), and FSTL3 siRNA (25 nM) (all from Santa Cruz Biotechnology), as well as siRNA for ID2 (150 nM) and CYR61 (25 nM) (both from GE Dharmacon).
Gene overexpression experiments. Induction of overexpression of PVRL2, FSTL1, and CYR61 was performed as previously described, with some modifications (4). ECs were transfected with 0.33 mg of FSTL1 or PVRL2 (or control vector pCMV6-XL5) or 1.65 mg of CYR61 (or control vector pCMV6-XL4) (all from Origene) and Lipofectamine 2000 (Invitrogen) for 24 hours in T12.5 flasks. Five hours after transfection, the culture medium was changed to allow the cells to grow in endothelial growth medium supplemented with bovine brain extract (Lonza). Thereafter, qPCR analyses or Matrigel tube formation assays were performed.
Enzyme-linked immunosorbent assay (ELISA). The levels of VEGF and bFGF in cell culture supernatants were measured using ELISA kits (R&D Systems). The absorbance of each well was read using a microplate reader at 450 nm.
Matrigel tube formation assay. A Matrigel tube formation assay was performed to evaluate the effect of HDAC-5 on angiogenesis (6) . Transfected SSc ECs were suspended in EBM-2 medium with 0.1% fetal bovine serum and plated in 8-well Lab-Tek chambers coated with growth factor-reduced Matrigel (BD Biosciences). The cells were fixed and stained after overnight incubation. Quantitation of the tubes formed by ECs was performed in a blinded manner by a researcher (MAA). Pictures of each well were taken using an EVOS XL Core Cell Imaging system (Life Technologies). In the doubleknockdown study, SSc ECs were transfected for 48 hours with control siRNA, HDAC5 siRNA, or HDAC5 plus the siRNA for genes of interest, and then plated on Matrigel. For the overexpression experiments, SSc ECs were transfected with control vector, FSTL1, PVRL2, or CYR61 and the Matrigel assay was carried out the next day.
Assay for transposase-accessible chromatin using sequencing (ATAC-seq). To characterize the impact of HDAC5 knockdown on chromatin accessibility at a genome-wide level, ATAC-seq was performed (14) . This utilizes a hyperactive Tn5 transposase that simultaneously cuts and ligates adaptors at regions of open chromatin. Since HDAC5 knockdown alters the chromatin structure, application of ATAC-seq in this study allowed us to assess genome-wide chromatin accessibility in SSc ECs with a high degree of accuracy and sensitivity. After transfection, 50,000 ECs were collected and lysed in 50 ml lysing buffer (10 mM Tris HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.1% Igepal CA-630). After centrifugation, the supernatant was discarded and the pellet was used for transposition. The transposition reaction included 25 ml 2 3 TD buffer (Illumina), 2.5 ml Tn5 transposase (Illumina), and 22.5 ml water. The mixture was incubated at 378C for 30 minutes. After purification, DNA libraries were prepared by PCR and purified using a Qiagen MinElute kit. To assess the quality of the DNA libraries, gel electrophoresis was performed and the DNA was visualized using Omega Lum C (Aplegen). Libraries that passed quality control measures, as previously described (14), were sequenced with 50-bp pair-end reads on an Illumina Hi-Seq 2500 platform (3 samples per lane).
ATAC-seq data analysis. Sequencing reads were aligned to the human genome assembly (hg19) using BurrowsWheeler Alignment (version 0.7.5) (15) . Improperly paired alignment and alignment with a mapping quality of ,4 were filtered using SAMtools (version 0.1.19) (16). Peak-calling was then performed using MACS2 (version 2.0.10) (17), with reads shifted and extended by the parameters "-nomodel -shift -100 -extsize 200 -B -broad". Blacklisted genomic regions (18) were removed from the peaks. Comparison of the findings in the cells under each knockdown condition (HDAC5 knockdown versus control siRNA treatment) was performed using diffReps (version 1.55.4) (19) , with the 3 individual experiments treated as triplicates for each condition. Running diffReps with a negative binomial model and a P value threshold of 1 3 10 24 identified peaks that had significantly different signal abundance (at a significance level of P , 0.05) between the 2 conditions, after adjustment with the Benjamini-Hochberg method.
Bioinformatics analysis. To identify genes that are relevant to SSc, genes that showed differential chromatin accessibility after HDAC5 knockdown in ECs were subjected to bioinformatics analysis using IRIDESCENT (20) . This analysis searches for co-occurrence of the genes and the key words (i.e., fibrosis or angiogenesis) within the scientific literature. A statistical method was used to score the relevance of the cooccurrence by comparing the observed frequencies to those randomly occurring by chance (20) .
Statistical analysis. Results are expressed as the mean 6 SD. To determine the differences between the groups (as shown in Figure 1 ), Mann-Whitney U test was performed using GraphPad Prism version 6. To compare the biomarkers in SSc ECs under each transfection condition (HDAC5 knockdown versus control siRNA treatment) (as shown in Table 3 ), a paired t-test was performed. P values less than 0.05 were considered statistically significant.
RESULTS
Aberrant expression of class II HDACs in SSc ECs. We examined the expression of class IIa and class IIb HDACs using qPCR. As shown in Figure 1A , expression of HDAC4 and HDAC5, both class IIa HDACs, was up-regulated in SSc ECs compared to healthy control ECs, whereas expression of HDAC6, a class IIb HDAC, was down-regulated (each P , 0.05). We further confirmed the increased expression of HDAC-5 in SSc ECs at the protein level ( Figure 1B) . Although HDAC-5 expression was variable among SSc patients, its expression was significantly increased in all SSc ECs (n 5 4; P , 0.05 versus healthy controls).
Since HDAC-5 is antiangiogenic, we proceeded to knock down HDAC5 mRNA in ECs and examined whether the decrease in HDAC5 expression altered the angiogenic ability of SSc ECs. We first established the optimal HDAC5 knockdown condition ( Figure 1C) . In healthy donor ECs, 75 nM of HDAC5 siRNA resulted in ;70% knockdown of HDAC5 when compared to cells transfected with control siRNA. We then used this condition in SSc ECs and achieved ;87% knockdown of HDAC5. Furthermore, in SSc ECs under this transfection condition, we confirmed that, at the protein level, HDAC-5 was indeed negligible ( Figure 1D ). Therefore, in subsequent experiments, the condition utilized for HDAC5 knockdown was a concentration of 75 nM siRNA for 48 hours.
Increase in tube formation following HDAC5 knockdown in SSc ECs. We then used a Matrigel tube formation assay to test whether a decrease in HDAC5 expression altered the angiogenic ability of SSc ECs. We first used ECs isolated from healthy subjects and from patients with SSc and performed a Matrigel tube formation assay. Similar to findings reported previously (3, 5, 7) , SSc ECs, in the absence of an angiogenic stimulus, were unable to form tube-like structures on Matrigel, whereas healthy donor ECs exhibited tube formation ( Figure 1E ). SSc ECs transfected with control siRNA also demonstrated a diminished capability to form tubes ( Figure 1F ). In contrast, knocking down HDAC5 restored the ability of SSc ECs to form tubes and resulted in an ;2-fold increase in the number of tubes formed (P , 0.05 versus control siRNA-treated cells).
Differential open-chromatin regions revealed by ATAC-seq after HDAC5 knockdown in SSc ECs. HDAC5 knockdown in SSc ECs showed that chromatin accessibility was increased when compared to that in SSc ECs treated with control siRNA (Figure 2A) . A total of 119 regions were identified as having at least a 20% fold difference in chromatin accessibility ($1.2-fold or #0.80-fold change in sequencing peak intensity; adjusted Figure 2 . Differential open-chromatin regions revealed by transposase-accessible chromatin using sequencing (ATAC-seq) assay after HDAC5 knockdown in endothelial cells (ECs) from patients with systemic sclerosis (SSc). A, Increased chromatin accessibility after HDAC5 knockdown, compared to control small interfering RNA (siRNA) transfection, in SSc ECs. With a cutoff value of 20% established for change in chromatin accessibility and a P value of ,0.05 (adjusted for multiple testing), a total of 119 regions were identified (85 regions with increased chromatin accessibility, and 34 regions with decreased chromatin accessibility). In the regions of increased chromatin accessibility, 75 genes were located in these sites and only 9 genes were located in less-accessible regions. B, University of California, Santa Cruz Genome Browser tracks of the FSTL3 locus along with data from ATAC-seq analysis of signals from control siRNA-treated or HDAC5 siRNA-treated samples, DNase I hypersensitivity (HS) mapping from human umbilical endothelial cells (HUVECs) (generated by the ENCODE project), and ChIP-seq data on H3K27Ac in HUVECs (from the ENCODE project). HDAC5 knockdown resulted in an increase in peak intensity compared to control siRNA treatment. The ATAC-seq signals were very similar to the DNase I hypersensitivity sequencing and overlapped H3K27Ac enrichment in HUVECs. C, IRIDESCENT analysis of genes located in the more-accessible chromatin regions after HDAC5 knockdown, to identify genes that were related to angiogenesis or fibrosis in SSc ECs.
HDAC5 OVEREXPRESSION AND IMPAIRED ANGIOGENESIS IN SCLERODERMAP , 0.05). Of those identified, 85 regions showed increased chromatin accessibility, and 34 regions showed decreased chromatin accessibility. In the regions of increased chromatin accessibility, we identified a total of 75 genes located in these sites (Figure 2A ). In contrast, only 9 genes were located in less-accessible regions. The genes that were located in the regions identified as more accessible to chromatin and having a 1.5-fold increase in peak intensity after HDAC5 knockdown, relative to control siRNA treatment, are listed in Table 2 .
As shown in Figure 2B (depicting genome tracks of the FSTL3 locus), knockdown of HDAC5 in SSc ECs increased the chromatin accessibility of FSTL3, as indicated by the increase in peak intensity as compared to that in control siRNA-treated cells. For validation, we compared our ATAC-seq data with chromatin-accessibility data sets such as DNase-seq. The ATAC-seq peaks correlated with DNase hypersensitivity regions generated in human umbilical vein ECs (generated by the University of Washington ENCODE group). In addition, we observed that our ATAC-seq data aligned with ChIP-seq peaks from the ENCODE project (21) for histone marks associated with active chromatin (H3K27Ac).
Up-regulation of genes involved in angiogenesis or fibrosis after HDAC5 knockdown. Bioinformatics analysis using IRIDESCENT revealed that among the genes that were located in the regions of increased chromatin accessibility in SSc ECs after HDAC5 knockdown, at least 16 genes appeared to be involved in angiogenesis and a few appeared to be involved in fibrosis ( Figure 2C ). Three genes were identified as possibly involved in both angiogenesis and fibrosis (CYR61, KRAS, and SOD2). We then examined the expression of these genes in SSc ECs under conditions of HDAC5 knockdown compared to control siRNA treatment. We found that 8 genes were significantly up-regulated after HDAC5 knockdown (P , 0.05) ( Table 3) . These included ID2, CTNNAL1, MBP, PVRL2, CYR61, FSTL1, FSTL3, and SQSTM1. 
TSOU ET AL
In addition to the genes identified by ATAC-seq, we also examined the expression of 2 proangiogenic factors, VEGF and bFGF, in SSc ECs. As shown in Figure 3A , levels of mRNA for both VEGF and bFGF were significantly up-regulated after HDAC5 knockdown. We also observed a 1.5-fold to 2-fold increase in protein levels of both VEGF and bFGF in culture supernatants of SSc ECs after HDAC5 knockdown (data not shown).
Identification of genes that play functional roles in HDAC5-mediated angiogenesis. We performed double-knockdown experiments to identify genes that led to an increase in tube formation after HDAC5 knockdown. We chose angiogenic genes that were significantly up-regulated after HDAC5 knockdown, as listed in Table  3 . These included ID2, CTNNAL1, PVRL2, and CYR61. In addition, FSTL1 and FSTL3 were also included, since, upon a comprehensive literature search, we determined that they appeared to be proangiogenic. MBP was excluded because we were unable to identify its role in angiogenesis. As shown in Figure 3B , in SSc ECs, when the expression of FSTL1, PVRL2, or CYR61 was knocked down together with the expression of HDAC5, the number of tubes formed on Matrigel decreased, whereas transfection of the cells with FSTL3, CTNNAL1, or ID2 siRNA had minimal effect, suggesting that HDAC5 mediates its antiangiogenic effect, at least in part, through alterations in the chromatin accessibility of FSTL1, PVRL2, and CYR61. To further confirm their roles, we overexpressed FSTL1, PVRL2, or CYR61 individually in SSc ECs. We found that increased expression of these genes led to an increase in the angiogenic ability of SSc ECs ( Figure 3C ).
DISCUSSION
In this study, we identified a novel epigenetic mechanism that contributes to the inhibition of angiogenesis in SSc. HDAC5, which was overexpressed in SSc ECs, inhibited angiogenesis by repressing proangiogenic genes. This was demonstrated by applying an ATACseq assay to assess changes in the chromatin state after HDAC5 knockdown, thereby identifying key genes located in regions with increased chromatin accessibility. Several angiogenic and fibrosis-related genes were pinpointed on the basis of our findings, which revealed significantly increased expression of these genes after HDAC5 knockdown. Among the proangiogenic genes identified by ATAC-seq assay, we showed that PVRL2, FSTL1, and CYR61 played critical roles in promoting angiogenesis in SSc ECs, since overexpression of these genes resulted in increased tube formation by SSc ECs, while knocking down these genes, in conjunction with knockdown of HDAC5, led to decreased tube formation.
It is apparent that epigenetic changes are involved in SSc vasculopathy, since the results showed that HDAC-5 was involved in impaired angiogenesis in SSc ECs. Indeed, our results complement the findings from studies of fibrosis, in which it was shown that histone acetylation patterns differed in SSc patients, and that the use of HDAC inhibitors showed promising antifibrotic effects both in vivo and in vitro (22, 23) . However, global inactivation of HDACs by nonspecific inhibitors may affect angiogenesis by modifying both pro-and antiangiogenic HDACs. These pan-HDAC inhibitors target class I, class II, and/or class IV HDACs that govern cell proliferation, differentiation, migration, and angiogenesis. They inhibit angiogenesis through VEGF and hypoxia-inducible factor (24, 25) , affect class IIb HDAC-mediated cell migration, and induce class I HDAC-mediated cell apoptosis (26) . Therefore, one should be cautious when using HDAC inhibitors to treat Our results are consistent with those from a study by Urbich et al, who found that HDAC5 knockdown led to an increase in tube formation by ECs on Matrigel (12) . They also showed that the target genes regulated by HDAC5 included FGF2, SLIT2, and EPHB4. We showed that bFGF (encoded by FGF2) was up-regulated after HDAC5 knockdown ( Figure 3A) , and also identified additional genes that are repressed by HDAC5, including PVRL2, FSTL1, and CYR61 (Table 3) . The discrepancies between our study and the study by Urbich et al might be attributable to the different types of ECs used, and the methods that were applied to identify genes were also different (ATAC-seq versus oligonucleotide array).
Of note, in our study, the discrepancy between the mRNA expression levels of bFGF and VEGF and the ATAC-seq results may seem contradictory; however, it is not uncommon for chromatin accessibility and gene expression to lack correlation with each other. As shown in Table 3 , only 8 of the 25 genes that showed a significant increase in chromatin accessibility had increased mRNA expression. These results point to the Figure 3 . Promotion of tube formation by several up-regulated proangiogenic factors after HDAC5 knockdown. A, Expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) mRNA was determined by quantitative polymerase chain reaction in endothelial cells (ECs) from patients with systemic sclerosis (SSc) after treatment with HDAC5 small interfering RNA (siRNA) or control siRNA. Increased expression after HDAC5 knockdown was observed in both cases. B, Tube formation was assayed on Matrigel (left) and quantified as the number of tubes formed (right) after SSc ECs (n 5 4 cell lines) were transfected with control siRNA, HDAC5 siRNA, or HDAC5 siRNA plus siRNA for the genes of interest. FSTL1, PVRL2, and CYR61 appeared to play a key role in promoting angiogenesis after HDAC5 knockdown, while FSTL3, CTNNAL1, and ID2 did not. C, Induced overexpression of FSTL1, PVRL2, and CYR61 resulted in increased tube formation by SSc ECs, as identified by Matrigel assay (left) and quantified as the number of tubes formed on Matrigel (right). Vectors pCMV6-XL5 and pCMV6-XL4 were used as controls. Results are the mean 6 SD.
importance of studying the epigenome and transcriptome simultaneously, because the integration of data obtained from both approaches would greatly facilitate the identification of target genes.
We identified several proangiogenic factors controlled by HDAC5 (Table 3) . CYR61 (also known as CCN1) is a member of the CCN protein family that binds to the extracellular matrix and supports angiogenesis (27) . In contrast to CCN2 (also known as connective tissue growth factor), which is profibrotic, CYR61 is antifibrotic through activation of an integrin/oxidative stress-mediated pathway (28). Saigusa et al showed that CYR61 is down-regulated in dermal small blood vessels of SSc patients compared to controls (29) . We postulate that the antifibrotic nature of this molecule should also play a significant role in inhibiting the fibrotic process in SSc, since it has been shown that CYR61 restricted fibrosis in several models of fibrosis, including the skin (28, 30, 31) . However, the role of CYR61 in SSc fibrosis awaits further investigation.
The role of FSTL1 in fibrosis has mainly been observed in experimental studies of pulmonary fibrosis; depletion or blockade of FSTL1 in mice attenuated bleomycin-induced lung fibrosis (32) . However, contradictory results were obtained in a mouse model of renal fibrosis (33) . Although our bioinformatics analysis showed that FSTL1 played a role solely in fibrosis ( Figure 2C ), upon a more detailed literature search, we found that it is also involved in EC proliferation and tube formation (34) . Although its role in SSc pathogenesis remains to be explored, it has been shown that FSTL1 levels are elevated in SSc serum (35) . In this study, we showed that the expression of FSTL1 increased after HDAC5 knockdown, a finding consistent with a previous study showing that FSTL1 is regulated by histone acetylation (36) .
PVRL2 is a cell adhesion molecule that connects to the actin cytoskeleton by binding to afadin (37) . The mechanism by which nectin-2 promotes angiogenesis is not known. It is possible that it is mediated directly by its cell adhesion properties, but also indirectly through afadin, which promotes angiogenesis (38) , or through interaction with other members of the adhesion molecule family (39) . As adhesion molecules have been suggested to play a role in the pathogenesis of SSc (2), our finding that PVRL2 improves the angiogenic ability of SSc ECs offers new insights into how these adhesion molecules are involved in this disease.
It appears that HDAC-5 also controls fibrosis through SSc ECs, as a few fibrotic genes, including FSTL1, FSTL3, and SQSTM1, were identified as being up-regulated after HDAC5 knockdown in our study (Table 3) . These genes are involved in both the TGFb pathway (FSTL1 and FSTL3) and the autophagy pathway (SQSTM1) (40, 41) . FSTL3 also plays a role in angiogenesis through the inhibition of activin A (42, 43) . However, in our study, simultaneous knockdown of HDAC5 and FSTL3 did not reverse the angiogenic phenotype of SSc ECs. Although autophagy has been shown to play a role in various fibrotic disorders, including SSc (44, 45) , whether SQSTM1 is critical warrants additional studies.
In addition to its role in angiogenesis, HDAC-5 appears to be involved in inflammation and immunity. It controls the inflammatory responses of macrophages and the functions of T cells (46, 47) . In addition, HDAC-5 negatively regulates chemokine and cytokine production in fibroblast-like synoviocytes in rheumatoid arthritis (48) . Therefore, it is also possible that HDAC-5 has functional roles in the inflammatory and autoimmune aspect of SSc pathogenesis.
In conclusion, our results clearly show that epigenetic mechanisms contribute significantly to impaired angiogenesis in SSc. Increased expression of antiangiogenic HDAC5 repressed several proangiogenic genes, resulting in dysregulated angiogenesis in SSc ECs. Coupling ATAC-seq with functional assays, we identified novel angiogenic and fibrotic genes that warrant additional studies to delineate their roles in the pathogenesis of SSc.
